105 / 1851
Program
name
Lead
organization
Design Histology Indication
# Expected
to accrue
Primary
outcome
measure(s)
Clinicaltrials.
gov
identifier
Dabrafenib and
trametinib in
BRAFV600E-
mutated rare
cancers
GlaxoSmithKline NR
BRAFV600E
mutation–
positive tumor:
including
anaplastic
thyroid cancer,
biliary tract
cancer,
gastrointestinal
stromal tumor
Advanced
disease without
standard
treatment
options
135
ORR
NCT02034110
Nonseminomato
us germ cell
tumor/nonsemin
omatous germ
cell tumor, hairy
cell leukemia,
WHO grade 1 or
2 glioma, WHO
grade 3 or 4
(high-grade)
glioma, multiple
myeloma, and
adenocarcinoma
of the small
intestine
Advanced
disease without
standard
treatment
options
ORR
Basket trials matching patients to therapies
based on molecular profiles